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Abstract 
This study examines how best to present information in an antidepressant print DTCA. The objectives of this study are to: (1) modify an 
antidepressant print advertisement to enhance consumers’ understanding of the presented information, (2) create a questionnaire to 
measure consumers’ recall of the information presented in an antidepressant print advertisement and (3) pilot test the study 
instruments by comparing consumers’ recall of the information in the antidepressant print advertisement between those who view the 
original advertisement and those who view the modified advertisement.  Modifications of the advertisement were based on the 
Explanatory Structure Building Model, findings from previous studies, and literature pertaining to the enhancement of the readability 
and comprehension of written health information. Data collection was conducted in three stages using mixed methods. This study 
details potential techniques that can be used to enhance the presentation of information in print DTCA in order to improve consumers’ 
recall of the information. Furthermore, this study shows that strategies to improve the presentation of information in print DTCA exist 
and that the strategies are feasible to apply. 
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Introduction 
Prevalence of direct-to-consumer advertising (DTCA), or 
“pharmaceutical-company sponsored advertising of 
prescription medicines that directly targets consumers via the 
mass media”1 has increased remarkably. As pharmaceutical 
companies increased the use of DTCA, debates about potential 
benefits and risks of DTCA to the public and the health care 
system intensified. Proponents of DTCA state that the 
advertisements provide consumers with valuable educational 
information that can bring financial and health related 
benefits.2,3 Opponents of DTCA state that the advertisements 
provide consumers with incomplete and biased information 
that may generate unnecessary visits and inappropriate 
requests for medications.1,3 In the midst of these debates, the 
Food and Drug Administration (FDA) created guidelines to 
regulate DTCA. Within the guidelines, the presentation of a fair 
balance between benefit and risk information in DTCA is 
considered to be a fundamental component because the FDA 
believes that consumers are more likely able to make informed 
and conscious evaluations and decisions when they are 
presented with both sides of the information.4,5  
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While presenting both the benefit and risk information is 
regarded as one of the important regulations, how the 
information is presented to consumers should be considered. 
Even though both benefit and risk information are present in 
DTCA, as the FDA guideline requires, they are presented 
differently.6 Benefit information is more likely to be presented 
in larger font sizes7,8 and usually requires lower readability 
skills.9 Therefore, it is simple for consumers to read, 
understand, and form their own gist about the benefit 
information. On the other hand, risk information is usually 
presented in smaller font sizes that can be easily ignored,10 
composed of long lists where it is difficult to recognize clinically 
important and unimportant information,11 and is often missing 
key pieces of information such as numeric descriptors for the 
incidence level of each side effect.6  The format in which risk 
information is presented makes it overwhelming for consumers 
to comprehend.12  Therefore, due to the differences in how the 
benefit and risk information are presented, how much of the 
benefit and risk information consumers are able to 
comprehend and process is questionable. 
 
More specific to the reading level required to understand the 
benefit and risk information in DTCA, previous research 
indicates that the literacy level required to understand the main 
text body of DTCA (where most of the benefit information is 
presented) is at a high-school reading level and the brief 
summary section (where most of the risk information is 
presented) is at a college reading level.10 However, according to 
the National Assessment of Adult Literacy (NAAL), 36% of 
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America’s adult population has a basic or below basic health 
literacy level; health literacy is defined as “the degree to which 
individuals have the capacity to obtain, process, and 
understand basic health information and services needed to 
make appropriate health decisions”.13  When considering that 
more than one-third of the adult US population has a basic or 
below basic health literacy level, DTCA information presented 
in a high-school or college reading level can be challenging for 
the average consumers to process and understand.  The 
educational value of DTCA, as the proponents stress, is at stake 
if consumers are challenged with understanding the presented 
information. Therefore, to enhance the educational value of 
DTCA, a study that examines how best to present both benefit 
and risk information in DTCA to ensure that consumers with a 
basic health literacy level are able to read and comprehend the 
information is necessary. 
 
Objective  
The objectives of this study are to: (1) modify an antidepressant 
print advertisement to enhance consumers’ understanding of 
the presented information, (2) create a questionnaire to 
measure consumers’ recall of the information presented in an 
antidepressant print advertisement and (3) pilot test the study 
instruments by comparing consumers’ recall of the information 
in the antidepressant print advertisement between those who 
view the original advertisement and those who view the 
modified advertisement.  
 
Methods 
Mixed methods were used to conduct the study. One-on-one, 
semi-structured interviews as well as focus group interviews 
were conducted to evaluate the modifications made to the 
original advertisement.  For the pilot study, an experimental 
design was used to compare consumers’ recall of information 
between those who view the original advertisement and those 
who view the modified advertisement. 
 
Advertisement Selection 
Antidepressants are one of the most prescribed drugs in the 
U.S.14 and they are among the top 10 heavily advertised classes 
of medications.15 In order to explore a medical condition that 
DTCA targets frequently, antidepressants were selected as the 
drug category for the study. More specifically, a DTCA for Pristiq 
(Desvenlafaxine), an antidepressant, was selected for this study 
(Figure 1).  
 
Advertisement Modification  
The modification of the advertisement was based on the 
Explanatory Structure Building (ESB) Model, findings from 
previous studies, and literature pertaining to the enhancement 
of the readability and comprehension of written health 
information.  
ESB model proposed by Yaros (2006) suggests methods to 
enhance readers’ interest in and comprehension of complex 
scientific news messages. The ESB model posits “readers with 
little or no expertise in science and technology will express 
more interest in the content when the content is structured for 
readers’ general world knowledge”.16 The model suggests two 
methods to simplify scientific messages: (1) organize the 
messages and (2) use familiar terminologies. First, when 
organizing the sequence of the message, it is suggested that 
instead of placing the most recent news first, recent news 
should be mixed with historical and contextual information, 
which increases readers’ familiarity with the message. Second, 
when referring to scientific terminologies, more generally 
known words should be used, and when it is necessary to use 
scientific terms, explanation of those terms’ meanings should 
be provided. In this study, ESB model was used to simplify the 
information contained in the advertisement by (1) rearranging 
the paragraphs following the model’s suggestions and (2) 
replacing scientific terms with more generally known words. 
When it was necessary to use scientific terms, explanation was 
provided. 
 
Techniques identified for improving the readability and 
comprehension of written health information from previous 
studies were also incorporated in modifying the advertisement. 
The techniques were: (1) Use simple plain language.17-22 Using 
plain language includes avoiding jargon and technical/medical 
words and using familiar words; however, when it is necessary 
to use technical/medical words, they must be defined.  (2) Keep 
sentences short – no more than 8 to 10 words.17-19,21,23 (3) Keep 
paragraphs short – no more than 10 lines.19  (4) Use the active 
voice.19,21 (5) Focus on key information and clearly state desired 
action and behavior.17,19,21  (6) Use header and bullets to 
organize information.19,21,22 (7) Use necessary visual images but 
avoid decorating the page.17,18,21,22,24 (8) Use at least 12-point 
font.18,21,22 (9) Avoid all capital letters, italics, and nontraditional 
fonts.18,22 (10) Leave plenty of white space around margins and 
between sections.21 
 
A graphic design artist aided with the modification of the 
format and presentation of the information in the 
advertisement. Overall, the modified advertisement used 
simple plain language by avoiding technical/medical words; was 
constructed with sentences that have 10 or fewer words; 
contained paragraphs with fewer than 10 lines; used the active 
voice; used headers, bullets, and table boxes to organize 
information; used at least 12-point font; and contained written 
information at or below an eighth grade reading level. In order 
to conduct the modifications, a one-page advertisement was 
expanded to a two-page advertisement (Figure 2). The back of 
the advertisement, where detailed side effect information is 
located, was not modified for the study. A registered 
pharmacist reviewed the modified advertisement to ensure all 
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written information in the modified advertisement was 
correctly reworded to have the equivalent meaning as the 
original advertisement. In addition, a regulatory affairs 
professional reviewed the modified advertisement for its 
compliance with federal regulations for drug advertising. 
 
Readability Measure 
Readability formulas are designed to provide an estimate of a 
written passage’s reading grade level.25 A number of readability 
formulas exist such as Simple Measure of Gobbledygook 
(SMOG), Suitability Assessment of Materials (SAM), Flesch-
Kincaid Grade level, and Gunning-Fogg Index.25 Researchers 
recommend using the SMOG to examine the reading levels of 
health related materials due to its high correlations with 
different readability formulas (i.e., accuracy), widespread use, 
simple directions and speed of use.25 For this study, to assess 
the readability level of the original and the modified print 
advertisement, the SMOG readability formula was used. SMOG 
readability formula showed that the original advertisement was 
at an eleventh grade reading level and the modified 
advertisement was at or below an eighth grade reading level. 
 
Creation of Recall of Information Questionnaire 
Ten true-false and 10 multiple-choice questions were 
developed to assess participants’ recall of the information 
presented in the advertisement (Appendix A). Previous studies 
that assessed recall of information in DTCA26,27,28 were used as 
guidance.  The questions were designed to be applicable to 
both the original and modified advertisements.  
 
Data Collection: Stages of Testing 
Once the modified advertisement and the recall of information 
questionnaire were created, three stages of testing were 
conducted. During the first stage, evaluation of the 
modifications made to the original advertisement was 
conducted. Furthermore, suggestions and comments were 
collected from the participants for additional refinement of the 
modified advertisement and the recall of information 
questionnaire. The second stage was conducted to make finer 
adjustments to both the modified advertisement and the 
questionnaire. In addition, consumers’ recall of the information 
between those who viewed the original advertisement and 
those who viewed the modified advertisement was explored.  
As this study was a preparation for a larger experimental design 
study, last stage of testing was conducted to assess the 
feasibility of implementing the full study as well as to confirm 
that no additional modifications were necessary to both the 
modified advertisement and the recall of information 
questionnaire. The three stages of testing were exempted from 
the Social and Behavioral Sciences Institutional Review Board at 
the University of Wisconsin-Madison. 
 
 
Stages of Testing - Stage 1 
After the first version of the modified advertisement (Figure 2) 
and the recall of information questionnaire (Appendix A) were 
created, one-on-one, semi-structured interviews were 
conducted with six participants.  Participants were selected 
through convenience sampling. All participants were asked to 
read both the original and the modified version of the 
advertisement then select an advertisement that they thought 
was easier to read and understand.  Next, they were asked 
open-ended questions regarding the layout and content of the 
two advertisements. Examples of the open-ended questions 
are: “For what reasons do you find it easier to read and 
understand? Please explain as many reasons as you would 
like.”, “How can we make the advertisement that you picked 
even more easier to read and understand?” and “What 
suggestions do you have for the headings of each section?”. 
Afterward, participants were asked to answer ten questions 
pertaining to the information presented in the advertisements 
while reading the questions out loud and thinking out loud.  
Three participants answered ten true/false questions and the 
other three participants answered ten multiple-choice 
questions.  Each interview lasted approximately 30 minutes.  All 
interviews were audio-recorded for accurate analysis. 
Suggestions and comments provided by the participants were 
discussed among the researchers and the graphic designer. 
Modifications to the advertisement and the questionnaire were 
conducted based on the suggestions and comments.  
 
Stages of Testing- Stage 2 
The second stage of the study utilized modified advertisement 
and recall of information questionnaire that resulted from 
stage 1. It was conducted with 18 participants selected through 
convenience sampling. The participants were first year 
undergraduate students at a large university in the Midwest 
enrolled in the Diversity, Health, and Healthcare course. The 18 
participants were randomly assigned to read either the original 
advertisement or the modified advertisement; nine 
participants were assigned to each group. The two groups were 
placed in separate rooms. A teaching assistant for the course 
guided the original advertisement group and the researcher 
guided the modified advertisement group. The procedure for 
the two groups was equivalent. Participants were given up to 
six minutes to read the advertisement. Afterward, they were 
asked to answer 20 questions (10 true-false and 10 multiple-
choice questions) pertaining to the information presented in 
the advertisement without having access to the advertisement. 
Participants were told to mark their answers on their own 
copies of the questionnaire. After the administration of the 
questionnaire, the advertisement was provided back to the 
participants and each group participated in a focus group. For 
the group that read the original advertisement, the modified 
version of the advertisement was provided along with the 
original version. The focus group was used to assess 
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participants’ reactions to the advertisements and the recall of 
information questionnaire. Also, it was used to gather 
additional suggestions about ways to improve the modified 
advertisement and the questionnaire. Examples of questions 
asked are: “What can we do to improve the questions?”, “What 
can we do to make the advertisement easier for consumers to 
read and understand?” and “What terminologies did you have 
a hard time understanding?”. The whole process took 
approximately 30 minutes. Suggestions and comments 
provided by the participants were discussed among the 
researchers and the graphic designer. Independent sample t-
tests were used to compare consumers’ recall of information 
between those who viewed the original advertisement and 
those who viewed the modified advertisement. 
 
Stages of Testing - Stage 3 
The last stage of the study utilized modified advertisement and 
recall of information questionnaire that resulted from stage 2. 
It was conducted with four participants. Participants were 
selected through convenience sampling. Two participants read 
the original advertisement and the other two read the modified 
advertisement. All four participants answered the same survey 
questionnaire to measure their recall of information. The 
survey was self-administered. 
 
Results 
Study - Stage 1 
Participant characteristics for stage 1 of the study are 
summarized in Table 1. Among the six participants, five 
participants stated that the modified advertisement was easier 
to read and understand due to the following reasons: (1) larger 
font size, (2) categorization of information using clear headers 
and bullets, (3) formatting: plenty of white space making it 
easier on the eyes, (4) usage of easy to read language, and (5) 
aesthetically more attractive. Only one participant preferred 
the original advertisement. This participant explained that the 
original advertisement was more preferable due to the fact that 
it had “less information to process” and it “does not go into as 
much details” as the modified advertisement.  
 
When asked for suggestions on how to improve the modified 
advertisement to be even more easier to read and understand, 
participants stated: (1) revise the wording of the headers 
“Problems with Other Drugs”, “Other Health Concerns” and 
“Other Safety Information”, participants commented that the 
word “Other” made it confusing, (2) use a bigger font or bold 
the headers of each section, (3) shorten the bulleted points 
under “Problems with Other Drugs” and “Other Health 
Concerns”, (4) differentiate the FDA and Pristiq contact 
information at the bottom of the advertisement, (5) break up 
information in the “Suicidality and Antidepressant Drugs” box 
into three separate paragraphs and (6) make drug name logo 
“Pristiq” stand out more.  
Above suggestions were taken into consideration in creating 
the second version of the modified advertisement. For the 
second version, following modifications were conducted: (1) 
Headings were modified - “Problems with Other Drugs” was 
changed to “Potential Drug Interactions”, “Other Health 
Concerns” was changed to “Health Concerns”, and “Other 
Safety Information” was changed to “Safety Information”. (2) 
For the suggestion on making the headers of each section more 
visible using bold or bigger fonts, the background purple color 
was lightened so the headings would become more prominent 
without altering the font. (3) The bulleted points under each 
heading were shortened under a direction of a licensed 
pharmacist. (4) For the contact information, since the purpose 
of providing the FDA contact information was for consumers to 
report negative side effects, FDA contact information was 
placed under the heading “Most Common Side Effects”. Only 
Pristiq contact information remained in the white space. (5) The 
information inside the “Suicidality and Antidepressant Drugs” 
box was separated into three different paragraphs while 
keeping the wording consistent with the original 
advertisement. Although participants wanted the drug name 
logo “Pristiq” to stand out more by using a larger font, this 
adjustment was not conducted. This was due to the fact that 
the goal of advertisement modification for this study was to 
enhance consumers’ understanding of the presented 
information by reorganizing and rewording the presented 
information while keeping the content, graphics and color 
schemes consistent with the original advertisement. The 
second version of the modified advertisement can be found in 
Figure 3. 
 
For the recall of information questionnaire, participants 
suggested: (1) rewording statements/questions to be more 
lucid, (2) for the multiple-choice questions, keeping consistency 
in how questions are asked (for example, either use or do not 
use an interrogative word throughout the multiple-choice 
section) and (3) having more variability in the answer choice for 
question 1 in the multiple-choice section – participants were 
not clear about the difference between choice b. bipolar 
disorder and choice c. depression. Revisions to the recall of 
information questionnaire were conducted to incorporate the 
suggestions. In the true and false question section, statements 
for questions 4, 5, 7, 8, 9 and 10 were reworded for clarification. 
For example, question 7 was revised from “It DOESN’T matter if 
you stop taking Pristiq anytime you want without talking to your 
doctor” to “If you want to stop taking Pristiq, you should talk to 
your doctor before stopping your dose.” In the multiple-choice 
section, questions 6, 8 and 9 were revised to not use 
interrogative words. For example, question 6 was revised from 
“What should be monitored while taking Pristiq?” to 
“__________ should be monitored while taking Pristiq.”  Lastly, 
answer choices for the question “Pristiq is a drug to treat 
________.” was revised from “a. high cholesterol, b. bipolar 
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disorder, c. depression, d. high blood pressure, and e. cannot 
remember” to “a. high cholesterol, b. asthma, c. depression, d. 
high blood pressure, and e. cannot remember”. Revised version 
of the questionnaire can be found in Appendix B. 
 
Study – Stage 2 
Participant characteristics for stage 2 of the study are 
summarized in Table 1. For suggestions on modifying the 
advertisement, participants stated the following: (1) move the 
Pristiq logo to the top and enlarge it, (2) move the ‘Suicidality 
and Antidepressant Drugs’ box to the bottom of the page while 
breaking up the information in the box into smaller paragraphs, 
(3) bold the last sentence, “PRISTIQ is not approved for use in 
children under 18”, in the ‘Suicidality and Antidepressant Drugs’ 
box and (4) for the statement, “Pristiq works on two chemicals 
on the brain”, name the two chemicals and explain what they 
are in lay terms. For the recall of information questionnaire, 
both focus groups thought the wording was easy to understand 
and further revision was not necessary. 
 
The above suggestions were considered, but to fulfill the 
purposes of the study and to meet the legal requirements, 
further modifications incorporating the new suggestions were 
not conducted. As stated previously, the purpose of this study 
was to reorganize and reword the presented information while 
keeping the content, graphics and color scheme consistent with 
the original advertisement. Therefore, moving or modifying the 
Pristiq logo (suggestion 1) and adding new information about 
the two chemicals (suggestion 4) was inappropriate for the 
study. In addition, to maintain the legal requirements, 
additional changes to the ‘Suicidality and Antidepressant Drugs’ 
box were not conducted (suggestions 2 and 3). 
 
For pilot testing of the recall of information questionnaire, 
information recall scores for each group (original 
advertisement group and modified advertisement group) can 
be found in Tables 2 and 3. Comparing the information recall 
scores between the two groups, the modified advertisement 
group had significantly higher score compared to the original 
advertisement group. The original advertisement group had a 
mean score of 15.89 with a standard deviation of 1.36 whereas 
the modified advertisement group had a mean score of 18.56 
with a standard deviation of 1.24 (p-value = 0.001) 
 
Study – Stage 3  
The last stage of testing preceded smoothly, supporting the 
feasibility of conducting the full study. Furthermore, 
participants had no additional comments or suggestions for the 
advertisement modification or the recall of information 
questionnaire. 
 
 
 
Discussion 
This study was conducted in order to create a modified 
advertisement that could enhance consumers’ understanding 
of the information contained in an antidepressant print DTCA 
and to create a questionnaire that could assess consumers’ 
recall of the presented information in the DTCA. Furthermore, 
pilot test was conducted to examine the information recall 
scores between those who viewed the original advertisement 
and those who viewed the modified advertisement. 
 
Advertisement Modification 
When viewing the modified advertisement, participants 
frequently stated that the advertisement was in a format that 
made them actually read the advertisement rather than simply 
glimpse through it. They also noted that compared to 
advertisements they have seen in other magazines, the 
modified advertisement was presented and organized in a way 
that was easier to read and easier on eyes which allowed them 
to read the front page of the advertisement entirely. 
Participants’ reactions coincide with findings from previous 
studies. Previously, researchers found that consumers 
preferred information in DTCA to be organized in boxes and 
believed that information organized in boxes was easy to read 
and understand.28,29 This contradicts the rationale of one 
participant who preferred the original advertisement. This 
participant stated that the original advertisement was easier to 
read due to the reasons that the advertisement had “less 
information to process” and it “does not go into as much 
details” compared to the modified advertisement. However, 
the original and modified advertisements had equal amount of 
information and equal depth of information. Information was 
only reorganized and reworded to enhance consumers’ 
comprehension. It could have been that the participant thought 
there was less information due to the method used in 
presenting the information in the original advertisement. The 
original advertisement did not organize information into 
various boxes; information was presented in one long 
paragraph. This format could have made the participant to 
glimpse through the information rather than read and process 
the information. For pharmaceutical companies to market their 
products, perhaps this is what pharmaceutical companies want 
consumers to do. They may want consumers to obtain the basic 
information (indication for the drug) but glimpse over the 
information regarding side effects. Furthermore, even though 
both benefit and risk information is presented in DTCA, this 
could be why the opponents of DTCA state that the 
advertisements provide consumers with incomplete and biased 
information that generate unnecessary visits and inappropriate 
requests for medications.1,3  
 
Recall of Information Questionnaire 
For the true-false question section, participants suggested 
clarifying statements so that it would be lucid. For example, few 
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commented that the statement “It DOESN’T matter if you stop 
taking Pristiq anytime you want without talking to your doctor.” 
was not lucid due to the fact that it had three negative words 
(doesn’t, stop, and without) in one sentence. Considering the 
comment, this statement was modified to “If you want to stop 
taking Pristiq, you should talk to your doctor before stopping 
your dose”, this statement was revised to omit the words 
“doesn’t” and “without”. Another example of confusion 
created by negative wording was with statement, “You can take 
Pristiq while nursing WITHOUT letting your doctor know.” This 
statement was changed to “If you’re nursing, you should let 
your doctor know before taking Pristiq.” After conducting these 
revisions, participants did not present any confusion about 
understanding the statements.  
 
For the multiple-choice question section, majority of the 
participants suggested keeping a consistency in how questions 
are asked. Originally, among the 10 multiple-choice questions, 
4 questions used interrogative words such as what, who, and 
when in asking the questions and 6 questions asked participants 
to choose words to fill in the blanks to complete the sentences. 
Participants commented that more time was needed to gain 
understanding of what to do to answer the questions due to the 
inconsistency in asking questions. Perhaps participants were 
frustrated that it was taking them longer to understand the 
question than to answer the question. Considering this 
comment, all multiple-choice questions were revised to keep 
consistency in how questions are asked. Questions in the 
multiple-choice section of the questionnaire were revised to 
have only one instruction. The instruction was “Please select 
the best answer for each of the blanks below. If you cannot 
remember the answer, please select ‘e’ for cannot remember.” 
 
In overall, participants appreciated having the answer category 
of “cannot remember” in both true-false and multiple-choice 
sections of the comprehension questionnaire. Participants 
commented that by having this answer category, it prevented 
them from guessing the answer when they did not know the 
answer.  
 
Pilot Testing – Information Recall Scores 
Differences were observed for the recall of information scores 
between those who viewed the original advertisement and 
those who viewed the modified advertisement. Participants 
who viewed the modified version of the advertisement had a 
higher information recall score compared to participants who 
viewed the original version of the advertisement. The 
difference was detectable even with small sample sizes 
selected from a homogenous group.  
 
Since this was a pilot study, the results obtained here can be 
used to calculate the sample size for a larger experimental 
study. From this study, the effect size came out to be 0.9. When 
type 1 error is set a 0.05 and power is set at 0.80, minimum 
number of 40 participants in total (20 participants per group) 
would be needed for the full study. However, consideration 
should be given since the participants who partook in this 
portion of the study were college students. Perhaps more 
conservative effect size should be utilized in calculating the 
sample size for the full study.  
 
Planned Future Study 
The advertisement used in this study promoted an 
antidepressant medication. Therefore, patient population in 
which depression is a common condition will be identified for 
participation for the future full study. A larger sample size will 
be utilized to examine whether the techniques used to modify 
the advertisement is successful in enhancing consumers’ recall 
of both the benefit and risk information presented in this print 
DTCA. In addition, to examine whether the modifications made 
to the DTCA is successful in enhancing recall of the information 
particularly among participants with basic or below basic health 
literacy level, participants’ health literacy level will be assessed 
using the Short Test of Functional Health Literacy in Adults         
(S-TOFHLA).  The S-TOFHLA measures an individual’s 
comprehension of written material rather than only her/his 
ability to read and correctly pronounce a list of words.30  The 
original Test of Functional Health Literacy in Adults (TOFHLA) 
takes up to 22 minutes to administer; this may cause 
respondent fatigue.  To overcome this barrier, the S-TOFHLA 
was developed; S-TOFHLA takes 7 minutes to administer.30,31  
Therefore, S-TOFHLA will be used for the full study to moderate 
participants’ total participation time. 
 
Conclusion 
The presentation of a fair balance between benefit and risk 
information is considered to be a fundamental part of the FDA’s 
guideline for DTCA. However, it is still apparent that benefit and 
risk information is presented differently in DTCA. This study 
details potential techniques that can be used to enhance the 
presentation of information in print DTCA in order to improve 
consumers’ recall of the information. This study validates that 
strategies to improve the presentation of information in print 
DTCA exist and that the strategies are feasible to apply. 
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Appendix A 
First version of the Comprehension Questionnaire 
 
Please answer true, false, or cannot remember to each of the questions below. 
 
ITEMS True False Cannot Remember 
1. You can only buy Pristiq with a prescription. 
   
2. Anyone with depression can take Pristiq. 
   
3. Pristiq is approved for use in children under 18. 
   
4. Taking Pristiq can make you sweat. 
   
5.  Taking Pristiq can increase your appetite. 
   
6. Pristiq does NOT make any other health conditions worse. 
   
7. It DOESN’T matter if you stop taking Pristiq anytime you want without 
talking to your doctor. 
   
8. Antidepressants can increase suicidal thoughts and behaviors in 
children only. 
   
9. If you are interested in taking Pristiq and you take aspirin on regular 
basis, you should let your doctor know. 
   
10. You can take Pristiq while nursing WITHOUT letting your doctor 
know. 
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Please select the best answer for each of the questions below. 
 
1. Pristiq is a drug to treat 
a. high cholesterol 
b. bipolar disorder 
c. depression 
d. high blood pressure 
e. cannot remember 
 
2. Pristiq is a(n) 
a. herbal medication 
b. prescription medication 
c. over-the-counter medication 
d. dietary supplement 
e. cannot remember 
 
3. Common side effects of Pristiq do not include 
a. nausea 
b. dizziness 
c. constipation 
d. increased appetite 
e. cannot remember 
 
4. You should not take Pristiq if you are taking 
a. Monoamine Oxidase Inhibitor (MAOI) 
b. allergy medications 
c. asthma medications 
d. vitamin supplements 
e. cannot remember 
 
5. Antidepressants can increase suicidal thoughts and behaviors in 
a. pregnant women 
b. adults over age 65 
c. tobacco users 
d. children, teens, and young adults 
e. cannot remember 
 
6. What should be monitored while taking Pristiq? 
a. body temperature 
b. blood pressure 
c. blood sugar level 
d. heart rate 
e. cannot remember 
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7. Pristiq works in 
a. the lungs 
b. the heart 
c. the brain 
d. the muscles 
e. cannot remember 
 
8. Who should not use Pristiq? 
a. children under age 18 
b. women above age 65 
c. men above age 65 
d. tobacco users 
e. cannot remember 
 
9. When you are taking Pristiq, what should you avoid doing? 
a. take vitamin supplement 
b. drink alcohol 
c. use tobacco products 
d. exercise 
e. cannot remember 
 
10. If you are planning to take Pristiq, you should tell your health care professional about the following except 
a. if you have high blood pressure 
b. if you have heart problems 
c. if you are nursing 
d. if you have asthma 
e. cannot remember 
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Appendix B 
Second (final) version of the Comprehension Questionnaire 
 
Please answer true, false, or cannot remember to each of the questions below. 
 
ITEMS True False Cannot Remember 
1. You can only buy Pristiq with a prescription. 
   
2. Anyone with depression can take Pristiq. 
   
3. Pristiq is approved for use in children under 18. 
   
4. Side effects of Pristiq include sweating. 
   
5.  Side effects of Pristiq include increased appetite. 
   
6. Pristiq does not make any other health conditions worse. 
   
7. If you want to stop taking Pristiq, you should talk to your doctor 
before stopping your dose. 
   
8. Antidepressants increase suicidal thoughts only in adults. 
   
9. If you are interested in taking Pristiq and you take aspirin on regular 
basis, you should talk to your doctor about it. 
   
10. If you’re nursing, you should let your doctor know before taking 
Pristiq. 
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Please select the best answer for each of the blanks below.  If you cannot remember the answer, please select ‘e’ for cannot 
remember. 
 
1. Pristiq is a drug to treat ___________. 
a. high cholesterol 
b. asthma 
c. depression 
d. high blood pressure 
e. cannot remember 
 
2. Pristiq is a(n) ___________. 
a. herbal medication 
b. prescription medication 
c. over-the-counter medication 
d. dietary supplement 
e. cannot remember 
 
3. Common side effects of Pristiq do not include ___________. 
a. nausea 
b. dizziness 
c. constipation 
d. increased appetite 
e. cannot remember 
 
4. You should not take Pristiq if you are taking ___________. 
a. Monoamine Oxidase Inhibitor (MAOI) 
b. allergy medications 
c. asthma medications 
d. vitamin supplements 
e. cannot remember 
 
5. Antidepressants can increase suicidal thoughts in ___________. 
a. pregnant women 
b. adults over age 65 
c. tobacco users 
d. children, teens, and young adults 
e. cannot remember 
 
6. ___________ should be monitored while taking Pristiq. 
a. Body temperature 
b. Blood pressure 
c. Blood sugar level 
d. Heart rate 
e. cannot remember 
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7. Pristiq works in ___________. 
a. the lungs 
b. the heart 
c. the brain 
d. the muscles 
e. cannot remember 
 
8. ___________ should not use Pristiq. 
a. Children under age 18 
b. Women above age 65 
c. Men above age 65 
d. Tobacco users 
e. cannot remember 
 
9. When you are taking Pristiq, you should avoid ___________. 
a. taking vitamin supplements 
b. drinking alcohol 
c. using tobacco products 
d. exercising 
e. cannot remember 
 
10. If you are planning to take Pristiq, you should tell your health care provider about the following except ___________. 
a. if you have high blood pressure 
b. if you have heart problems 
c. if you are nursing 
d. if you have asthma 
e. cannot remember 
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Figure 1 
One-page original Pristiq print advertisement from 2010 (size: approximately 27.5cm by 20cm) 
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Figures 2 
First version of modified two-page print advertisement for Pristiq 
(size: approximately 27.5cm by 41cm) 
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Figures 3 
Second/final version of modified two-page print advertisement for Pristiq 
(size: approximately 27.5cm by 41cm) 
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Table 1 
Participant Characteristics (Stage 1 Participant n=6; Stage 2 Participant n = 18) 
 
 
 
Characteristics 
Stage 1 Participant 
Characteristics 
n (%) 
Stage 2 Participant 
Characteristics 
n (%) 
Mean age  28 18 
Gender   
Female 5 (83.3) 16 (88.9) 
Male 1 (16.7) 2 (11.1) 
Race   
Asian 2 (33.3) 0 
Hispanic/Latino 2 (33.3) 0 
White 2 (33.3) 17 (94.4) 
Unidentified 0 1 (5.6) 
Education completed   
Associate degree 1 (16.7) 
Not Applicable* Bachelor degree 3 (50) 
Graduate degree 2 (33.3) 
Use of Pristiq   
Yes 0 0 
No 6 (100) 18 (100) 
Family/friend’s use of Pristiq 
Yes 0 0 
No 6 (100) 18 (100) 
Seen/Heard Pristiq Ad 
Yes 3 (50) 8 (44.4) 
No 3 (50) 10 (55.6) 
*All stage 2 participants were first year undergraduate students at a large university. 
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Table 2 
Total score for the comprehension questionnaire from Stage 2 (n=18) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
Comprehension score comparison (n=18) 
 
 Original Advertisement Mean score ± SD 
Modified Advertisement 
Mean score ± SD P-value 
Comprehension Score 15.89 ± 1.36 18.56 ± 1.24 0.001 
 
 
Number of items 
correct 
Group 
Original Ad Group Modified Ad Group 
14 2 0 
15 1 0 
16 3 0 
17 2 2 
18 1 3 
19 0 1 
20 0 3 
